Microencapsulation of chloroquine diphosphate by Eudragit RS100

Area of Science:

• Pharmaceutical Technology
• Drug Delivery Systems
• Materials Science

Background:

• Chloroquine diphosphate is a highly water-soluble antimalarial drug.
• Effective drug delivery systems are needed to control release and improve patient compliance.
• Taste masking is a significant challenge for oral drug formulations.

Purpose of the Study:

• To develop and characterize microcapsules of chloroquine diphosphate.
• To evaluate the in vitro drug release profile and taste masking efficacy.
• To explore the potential of Eudragit RS100 for controlled drug delivery.

Main Methods:

• Non-solvent addition coacervation method using Eudragit RS100 as coating material.
• Tetrahydrofuran (THF) as the liquid manufacturing vehicle and cyclohexane as the non-solvent.
• Polyisobutylene (PIB) used as an anti-aggregating agent.
• Characterization included particle size, shape, total drug content, in vitro release, and taste tests.

Main Results:

• Successful encapsulation of chloroquine diphosphate into Eudragit RS100 microcapsules.
• In vitro drug release studies demonstrated a prolonged release effect.
• Taste tests indicated significant masking of the bitter taste of chloroquine diphosphate.
• Particle size and shape were evaluated for formulation quality.

Conclusions:

• The non-solvent addition coacervation method is effective for producing chloroquine diphosphate microcapsules.
• The developed microcapsules offer a promising approach for prolonged drug release and taste masking.
• Eudragit RS100 is a suitable material for creating taste-masked, controlled-release formulations.